Allogene Therapeutics, Inc.
ALLO
$1.21
-$0.01-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.22% | 13.68% | 21.29% | 17.64% | 23.44% |
| Total Depreciation and Amortization | -11.25% | -7.47% | -3.94% | 0.67% | 1.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.66% | -15.61% | -26.23% | 0.88% | -6.54% |
| Change in Net Operating Assets | 70.79% | 11.90% | -29.74% | -626.03% | -321.51% |
| Cash from Operations | 24.46% | 13.07% | 15.75% | 11.71% | 4.00% |
| Capital Expenditure | -312.44% | -60.53% | 54.22% | 79.58% | 93.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.12% | -17.07% | -53.65% | -40.16% | -37.38% |
| Cash from Investing | -77.72% | -17.60% | -53.65% | -39.34% | -36.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.48% | 29.04% | 19.54% | 13.83% | 21.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 202.98% | -- | -- | -- | -- |
| Cash from Financing | -77.78% | 34.93% | 21.92% | 16.22% | 24.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -843.82% | 85.42% | -137.35% | -252.32% | -72.91% |